CN104583225A - 艾杜糖-2-硫酸酯酶的纯化 - Google Patents

艾杜糖-2-硫酸酯酶的纯化 Download PDF

Info

Publication number
CN104583225A
CN104583225A CN201380042665.2A CN201380042665A CN104583225A CN 104583225 A CN104583225 A CN 104583225A CN 201380042665 A CN201380042665 A CN 201380042665A CN 104583225 A CN104583225 A CN 104583225A
Authority
CN
China
Prior art keywords
restructuring
purifying
albumen
methods according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380042665.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·尼科尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Human Genetics Therapies Inc
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104583225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Priority to CN201710840704.3A priority Critical patent/CN107596358A/zh
Priority to CN201710840314.6A priority patent/CN107596357A/zh
Publication of CN104583225A publication Critical patent/CN104583225A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201380042665.2A 2012-06-29 2013-06-28 艾杜糖-2-硫酸酯酶的纯化 Pending CN104583225A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710840704.3A CN107596358A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化
CN201710840314.6A CN107596357A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
US61/666,733 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710840314.6A Division CN107596357A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化
CN201710840704.3A Division CN107596358A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化

Publications (1)

Publication Number Publication Date
CN104583225A true CN104583225A (zh) 2015-04-29

Family

ID=49778401

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201710840314.6A Pending CN107596357A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化
CN201710840704.3A Pending CN107596358A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化
CN201380042665.2A Pending CN104583225A (zh) 2012-06-29 2013-06-28 艾杜糖-2-硫酸酯酶的纯化

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201710840314.6A Pending CN107596357A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化
CN201710840704.3A Pending CN107596358A (zh) 2012-06-29 2013-06-28 艾杜糖‑2‑硫酸酯酶的纯化

Country Status (38)

Country Link
US (6) US9051556B2 (ru)
EP (2) EP3441398A1 (ru)
JP (4) JP6171007B2 (ru)
KR (5) KR101380740B1 (ru)
CN (3) CN107596357A (ru)
AR (1) AR091647A1 (ru)
AU (3) AU2013282395C1 (ru)
BR (1) BR112014032567B1 (ru)
CA (2) CA3008945A1 (ru)
CL (1) CL2014003567A1 (ru)
CO (1) CO7240396A2 (ru)
CR (1) CR20140588A (ru)
CY (1) CY1121519T1 (ru)
DK (1) DK2867245T3 (ru)
DO (1) DOP2014000294A (ru)
EA (2) EA034549B1 (ru)
ES (1) ES2689468T3 (ru)
GT (1) GT201400303A (ru)
HK (4) HK1209431A1 (ru)
HR (1) HRP20181897T1 (ru)
HU (1) HUE040769T2 (ru)
IL (4) IL236315A (ru)
LT (1) LT2867245T (ru)
MX (3) MX336715B (ru)
MY (3) MY157087A (ru)
NZ (3) NZ733366A (ru)
PE (1) PE20150720A1 (ru)
PH (3) PH12014502871A1 (ru)
PL (1) PL2867245T3 (ru)
PT (1) PT2867245T (ru)
RS (1) RS58005B1 (ru)
SG (2) SG11201408761VA (ru)
SI (1) SI2867245T1 (ru)
TR (1) TR201815811T4 (ru)
TW (2) TWI553120B (ru)
UA (1) UA121959C2 (ru)
WO (1) WO2014005014A2 (ru)
ZA (2) ZA201409397B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045727A1 (zh) * 2016-09-06 2018-03-15 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2018038243A1 (ja) 2016-08-25 2018-03-01 Ｊｃｒファーマ株式会社 抗体融合蛋白質の製造方法
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
EP3692070A1 (en) 2017-10-02 2020-08-12 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
WO2020132452A1 (en) * 2018-12-20 2020-06-25 Shire Human Genetic Therapies, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
AU2021364779A1 (en) * 2020-10-23 2023-06-01 Alexion Pharmaceuticals, Inc. Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096555A (en) * 1995-07-26 2000-08-01 Dade Behring Marburg Gmbh Process for characterizing the glycosylation of glyco-proteins and for the in vitro determination of the bio-availability of glyco-proteins
US7323553B2 (en) * 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
US7541164B2 (en) * 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011044542A1 (en) * 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011163652A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
EP0750511B1 (en) 1994-03-16 2003-06-11 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2000050443A2 (en) 1999-02-26 2000-08-31 Millennium Pharmaceutcals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
ATE348173T1 (de) 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
AU7099200A (en) 1999-09-03 2001-04-10 Human Genome Sciences, Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
JP2004502404A (ja) 2000-02-17 2004-01-29 インサイト・ゲノミックス・インコーポレイテッド ヒトキナーゼ
AU2001252917A1 (en) 2000-03-17 2001-10-03 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
WO2004072275A2 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
EP1713904B1 (en) 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
JP6045492B2 (ja) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CN103153337A (zh) * 2010-09-28 2013-06-12 共立制药股份有限公司 黏膜佐剂组合物
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096555A (en) * 1995-07-26 2000-08-01 Dade Behring Marburg Gmbh Process for characterizing the glycosylation of glyco-proteins and for the in vitro determination of the bio-availability of glyco-proteins
US7323553B2 (en) * 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
US7541164B2 (en) * 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2011044542A1 (en) * 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011163652A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045727A1 (zh) * 2016-09-06 2018-03-15 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用

Also Published As

Publication number Publication date
US20140004096A1 (en) 2014-01-02
US9492511B2 (en) 2016-11-15
US20210317426A1 (en) 2021-10-14
CA3008945A1 (en) 2014-01-03
MY157087A (en) 2016-04-19
UA121959C2 (uk) 2020-08-25
EP2867245A4 (en) 2016-03-09
ES2689468T3 (es) 2018-11-14
KR101380740B1 (ko) 2014-04-11
BR112014032567B1 (pt) 2022-09-13
ZA201803289B (en) 2021-04-28
CO7240396A2 (es) 2015-04-17
US20170073652A1 (en) 2017-03-16
PH12020500027A1 (en) 2021-03-15
JP2015523072A (ja) 2015-08-13
HUE040769T2 (hu) 2019-03-28
WO2014005014A3 (en) 2014-02-27
IL236315A (en) 2016-11-30
CN107596357A (zh) 2018-01-19
IL261264A (en) 2018-10-31
JP6505629B2 (ja) 2019-04-24
EA201492177A1 (ru) 2015-06-30
JP2016119911A (ja) 2016-07-07
CL2014003567A1 (es) 2015-04-24
TW201703794A (zh) 2017-02-01
HRP20181897T1 (hr) 2019-01-11
PE20150720A1 (es) 2015-05-16
DK2867245T3 (en) 2018-11-26
SG10201703489VA (en) 2017-05-30
EA202090044A1 (ru) 2020-07-31
BR112014032567A2 (pt) 2017-08-01
MX2019008914A (es) 2019-09-26
SG11201408761VA (en) 2015-01-29
KR20190064542A (ko) 2019-06-10
US20150313972A1 (en) 2015-11-05
RS58005B1 (sr) 2019-02-28
HK1249026A1 (zh) 2018-10-26
GT201400303A (es) 2017-08-31
AU2018200230B2 (en) 2020-01-02
EP3441398A1 (en) 2019-02-13
EP2867245B1 (en) 2018-09-12
NZ703093A (en) 2017-08-25
JP6171007B2 (ja) 2017-07-26
KR20200143339A (ko) 2020-12-23
EP2867245A2 (en) 2015-05-06
AU2013282395B2 (en) 2015-12-03
PH12014502871B1 (en) 2015-02-23
HK1209431A1 (en) 2016-04-01
IL287057A (en) 2021-12-01
CY1121519T1 (el) 2020-05-29
CN107596358A (zh) 2018-01-19
EA034549B1 (ru) 2020-02-19
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
PT2867245T (pt) 2018-11-26
CA2877517C (en) 2018-07-31
WO2014005014A2 (en) 2014-01-03
JP2018121645A (ja) 2018-08-09
ZA201409397B (en) 2019-10-30
US20240043817A1 (en) 2024-02-08
MY192068A (en) 2022-07-25
PL2867245T3 (pl) 2019-02-28
MX2015000190A (es) 2015-04-08
US20190359958A1 (en) 2019-11-28
PH12015502408A1 (en) 2018-03-26
NZ743910A (en) 2019-12-20
US11530393B2 (en) 2022-12-20
JP2020105209A (ja) 2020-07-09
IL236315A0 (en) 2015-02-26
TWI553120B (zh) 2016-10-11
TR201815811T4 (tr) 2018-11-21
CA2877517A1 (en) 2014-01-03
AU2013282395A1 (en) 2015-01-29
MX336715B (es) 2016-01-28
AU2016200469B2 (en) 2017-10-12
AU2018200230A1 (en) 2018-02-01
LT2867245T (lt) 2018-11-12
SI2867245T1 (sl) 2018-12-31
HK1249027A1 (zh) 2018-10-26
KR20220002227A (ko) 2022-01-06
AU2013282395C1 (en) 2016-03-24
NZ733366A (en) 2019-12-20
US10344270B2 (en) 2019-07-09
MX366906B (es) 2019-07-30
TWI587869B (zh) 2017-06-21
PH12015502408B1 (en) 2018-03-26
KR20140002451A (ko) 2014-01-08
US9051556B2 (en) 2015-06-09
IL248727A0 (en) 2017-01-31
AR091647A1 (es) 2015-02-18
IL261264B (en) 2021-10-31
MY180287A (en) 2020-11-27
KR20140004603A (ko) 2014-01-13
PH12014502871A1 (en) 2015-02-23
AU2016200469A1 (en) 2016-02-18
DOP2014000294A (es) 2015-03-15
TW201410868A (zh) 2014-03-16

Similar Documents

Publication Publication Date Title
CN104583225A (zh) 艾杜糖-2-硫酸酯酶的纯化

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1209431

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150429